Amazentis usa

What Amazentis usa does

Amazentis is a Swiss longevity-biotech company founded in 2007 at the EPFL Innovation Park in Lausanne, that pioneered the clinical science of Urolithin A, a postbiotic molecule which triggers mitophagy — the cellular process that clears damaged mitochondria. The company's core technology is Mitopure®, a proprietary, >98% pure, clinically validated form of Urolithin A that delivers a calibrated dose independent of the consumer's gut microbiome (noting that only 30–40% of people produce meaningful Urolithin A from dietary sources such as pomegranate). The technology is supported by 18 years of dedicated research, 25 registered human clinical trials enrolling 2,200+ participants, 100+ global patents, FDA GRAS status, NSF certification, and peer-reviewed publications in Nature Medicine, JAMA Network Open, Cell Reports Medicine, and Nature Aging.

Amazentis operates a dual go-to-market model. On the consumer side, the company markets the Timeline brand — a vertical longevity brand selling Mitopure®-based supplements and skincare directly through the timeline.com e-commerce platform, supported by a recurring subscription model. On the B2B side, the company licenses Mitopure® as an ingredient to major consumer-goods companies; Nestlé Health Science has been an equity partner and global licensee since 2019, and L'Oréal's BOLD venture fund led the 2024 CHF 56M Series D and is commercializing Mitopure® in longevity dermo-cosmetics. The end customer base comprises health-conscious adults seeking scientifically validated interventions for age-related mitochondrial decline, supported by a network of recommending healthcare professionals.

The company was originally incorporated in Switzerland and reports a small headcount consistent with a research-led biotech transitioning into commercial scale. Funding to date totals approximately CHF 56M disclosed across the 2024 Series D plus an unquantified Nestlé Health Science equity stake in 2019. The company was recognized as a Top 40 winner in XPRIZE Healthspan 2025, providing third-party validation of its scientific approach. Management is led by CEO Brian Ray, Co-founder & President Chris Rinsch PhD, CMO Federico Luna, CFO Erik Schmitt, and Chief Medical Officer Dr. Anurag Singh, with a scientific advisory board anchored by EPFL faculty including Dr. Johan Auwerx, the foundational Urolithin A researcher.

Name

Amazentis usa

Legal name

Amazentis

Website

https://amazentis.com

Company type

Private

Founded year

2007

Operating status

Operating

Short description

Amazentis is a Swiss longevity-biotech company that pioneered Mitopure®, a proprietary >98% pure Urolithin A ingredient activating mitophagy for cellular renewal. It commercializes the ingredient through its Timeline consumer supplement and skincare brand and licenses it to Nestlé Health Science and L'Oréal.

Ownership category

akta.pro rank

Product category

Longevity Nutritional Supplements

NAICS

Medicinal and Botanical Manufacturing (325411)

SIC

Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Condition-Specific Bioactives (Glucosamine/Chondroitin, Plant Sterols, Melatonin, Lutein/Zeaxanthin) (AFAJAKAK)

Keywords

• Urolithin A supplements
• Mitophagy activation
• Longevity skincare
• Mitochondrial health
• Cellular nutrition

Headquarters

HQ city

Lausanne

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain, Others

Revenue model

1. Consumer Products (Timeline Brand): Direct-to-consumer sales of supplements and skincare products containing Mitopure®, sold through the Timeline e-commerce platform (timeline.com). Products include cellular nutrition supplements and longevity skincare.
2. B2B Ingredient Licensing: Licensing of Mitopure® proprietary ingredient to consumer goods partners including Nestlé Health Science and L'Oréal for use in their health and beauty products.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Amazentis develops Mitopure®, a proprietary >98% pure form of Urolithin A, a postbiotic clinically shown to activate mitophagy and support mitochondrial renewal. The company delivers Mitopure® to consumers through its Timeline brand (supplements and longevity skincare) and licenses the proprietary ingredient to enterprise partners including Nestlé Health Science and L'Oréal for use in their health and beauty products.

Product overview

Amazentis is a Swiss longevity-biotech company that pioneered the science of Urolithin A. The company operates a single-platform architecture centered on Mitopure®, its proprietary Urolithin A ingredient at >98% purity. This core ingredient is delivered to consumers through Timeline, the company's vertical consumer brand offering supplements and skincare products. The portfolio includes the Mitopure® molecule/formulation for cellular nutrition, Timeline supplements for internal longevity support, and Timeline skincare for topical mitochondrial science applications.

Differentiator

Problem solved

Functional benefit

Brands

• Timeline: The consumer longevity brand from Amazentis delivering Mitopure® Urolithin A supplements and skincare products worldwide.
• Mitopure®

Products and services

• Mitopure® Amazentis's proprietary, >98% pure, clinically validated form of Urolithin A — a postbiotic that triggers mitophagy to clear damaged mitochondria and support cellular renewal. Sold as a licensed ingredient to consumer goods partners.
• Timeline Longevity Supplements Consumer supplement brand delivering Mitopure® Urolithin A for cellular nutrition and longevity support, marketed to health-conscious adults seeking clinically validated anti-aging interventions. Sold direct-to-consumer through timeline.com.
• Timeline Longevity Skincare Topical skincare products applying mitochondrial science to skin aging, leveraging Urolithin A's effect on skin mitochondrial function and collagen assembly. Developed in partnership with L'Oréal.

Quantifiable outcome

• 500mg Mitopure® delivers at least 6x higher Urolithin A plasma levels over 24 hours compared to 8oz of pomegranate juice (NOURISH Study)
• +2 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• EPFL (École Polytechnique Fédérale de Lausanne)coreStrategic or Co-development PartnerAmazentis was founded at EPFL Innovation Park in 2007. The company's foundational research was conducted with EPFL's Auwerx lab, including the landmark 2016 Nature Medicine paper on Urolithin A and mitophagy. Multiple scientific advisors are EPFL faculty including Dr. Johan Auwerx and Dr. Patrick Aebischer (former EPFL President).

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Elysium Health: Direct-to-consumer longevity supplement company built around clinically validated NAD+ precursor (Basis); competes with Amazentis/Timeline in the same 'evidence-based healthy aging' supplement category targeting health-conscious adults.
• Life Extension: Long-established consumer supplement retailer with a strong longevity/healthy aging portfolio; competes for the same health-conscious consumer wallet share as Timeline and shares an evidence-led, nutraceutical-ingredient positioning.
• ChromaDex: Science-driven NAD+/NMN ingredient and consumer brand company (Tru Niagen) targeting cellular aging and mitochondrial health — directly comparable business model of proprietary ingredient + consumer brand + B2B licensing.
• Calerie Health: Premium longevity/healthy aging supplement brand with a clinically positioned product line; competes in the same evidence-led longevity category targeting middle-aged and older adults.

Emerging players

• Insilico Medicine: AI-driven longevity biotech developing therapeutics for age-related diseases; competes for the same scientific and venture narrative around aging biology but at a pharmaceutical rather than nutraceutical stage.
• InsideTracker: Personalized healthspan platform combining blood biomarker testing with supplement recommendations; targets the same health-conscious longevity persona and represents an emerging adjacent model that could disintermediate single-ingredient brands like Timeline.
• BioAge Labs: Clinical-stage biotech identifying drug targets that drive aging, including metabolic and mitochondrial pathways; represents a pharmaceutical-grade competitive threat to nutraceutical-grade longevity claims over time.
• Ambrosia (Young Plasma / clinical longevity): Early clinical-stage longevity player exploring plasma-based interventions for age-related decline; addresses the same 'healthspan' consumer and signals the breadth of experimental modalities competing for the longevity category.

Broad incumbents

• L'Oréal: Global beauty incumbent and lead investor in Amazentis's 2024 Series D via its BOLD venture fund; comparable on the dermo-cosmetic skincare side, where Mitopure® is being incorporated into longevity beauty products.
• Nestlé Health Science: Global consumer health and nutrition subsidiary of Nestlé and an Amazentis investor/partner since 2019; broad portfolio of medical nutrition and supplements gives it incumbent scale that Amazentis partners with rather than competes against.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amazentis

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amazentis usa